Biotehnos Listed by lamashtu Ransomware Group: Ransomware Claim — What’s Alleged & What To Do

Biotehnos, a Romanian pharmaceutical company, was listed on April 16, 2026, by the ransomware group lamashtu. The listing states that internal files were exfiltrated during a ransomware attack. No information has been released on the number of individuals affected or the volume of data involved. The incident reflects ongoing ransomware activity that targets organisations holding sensitive operational and research records. Such listings appear regularly on threat-actor sites, though independent confirmation of the underlying events remains limited to the group’s own statements.

Inside the incident

The only confirmed detail is the April 16, 2026, listing by lamashtu. The group claims internal files were taken during a ransomware operation. No public statement from Biotehnos has addressed the listing, and no figures for affected records, affected individuals, or the date of the alleged intrusion have been disclosed.

Inside lamashtu

Lamashtu is a ransomware operator that follows the double-extortion model common among current groups. It typically encrypts systems and removes copies of data before demanding payment. The group maintains a leak site where it lists organisations it claims to have compromised, posting samples or directories to pressure victims. Public reporting on the actor shows repeated targeting of mid-sized companies in regulated sectors, though each listing remains an unverified claim until corroborated by the victim or independent investigation.

About Biotehnos

Biotehnos was founded in 1993 by Prof. Dr. Ioan Manzatu and is headquartered in Otopeni, Ilfov County, near Bucharest. The company marked its 30th anniversary in 2023 and operates in the pharmaceutical sector, where organisations routinely maintain records related to product development, regulatory submissions, manufacturing processes, and commercial agreements.

What was likely exposed

The listing refers only to “internal files exfiltrated in ransomware attack.” No further breakdown of file categories or data fields has been published. Pharmaceutical companies commonly store research documentation, quality-control records, employee information, and contractual material, yet the precise contents of any exfiltrated material in this case remain unconfirmed.

The real-world impact

Exposure of internal pharmaceutical files can create operational disruption if the data includes proprietary processes or regulatory submissions. For individuals whose information appears in such files, the main risks involve potential misuse of personal or employment details. The organisation faces possible regulatory scrutiny and the cost of restoring systems and reviewing access controls, though the scale of these effects cannot be assessed from currently available information.

What to do if you're exposed

Individuals who believe their information may be involved should monitor accounts for unusual activity and consider placing fraud alerts with credit agencies. Changing passwords for any associated services and enabling multi-factor authentication reduces further risk. Readers can run a free exposure scan of their email address against known breach data to check for prior appearances.

• Review bank and credit statements regularly for unauthorised transactions.
• Request copies of personal records held by the organisation if contact details are known.
• Keep software and devices updated to limit additional exposure vectors.

AICompiled with AI assistance from public sources and published under our editorial standards.